Defining the Fc-correlates of protection against influenza

定义流感保护的 Fc 相关因素

基本信息

  • 批准号:
    10599256
  • 负责人:
  • 金额:
    $ 60.13万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-03-11 至 2025-02-28
  • 项目状态:
    未结题

项目摘要

Abstract The NIAID has named the development of a universal influenza vaccine as one if its key research goals, and this need will not be met with traditional vaccine design. The design of a globally protective vaccine against influenza has been hampered by the lack of a clear and definable correlate of immunity against influenza. The current correlate of protection from influenza infection, used to evaluate seasonal influenza vaccines, is the hemagglutination inhibition (HAI) titer, an indirect measure of virus neutralization by antibodies. However, HAI incompletely explains protection from seasonal influenza infection in humans. Conversely, extra-neutralizing antibody-dependent innate immune effector functions, including antibody dependent cellular cytotoxicity (ADCC), antibody dependent phagocytosis (ADCP), and antibody dependent complement activation (ADC), have all been implicated in protection in mice. However, it is uncertain whether non-neutralizing functions contribute to protection in humans. Thus, here we aim to exploit a comprehensive, agnostic, sample-sparing humoral profiling tool - that broadly captures Fc-profile diversity at unprecedented depths - to define the extra-neutralizing profiles of antibodies that track with protection against influenza in humans. Two unique cohorts of well characterized vaccinees will be profiled to define correlates of protection and correlates of the evolution of neutralizing antibody breadth. Linked to mechanistic dissection in mice, correlates will be dissected to define mechanistic links to guide the development of next generation vaccine strategies aimed at inducing functional-broadly neutralizing antibodies against influenza.
摘要 NIAID已将开发通用流感疫苗列为其重点研究之一 这一需求将无法通过传统的疫苗设计来满足。设计一个全球 由于缺乏一个明确和可定义的疫苗, 与流感免疫力相关。当前预防流感的相关因素 用于评估季节性流感疫苗的血凝抑制(HAI) 滴度,抗体中和病毒的间接量度。然而,HAI不完全 解释保护人类免受季节性流感感染。相反, 抗体依赖性先天免疫效应子功能,包括抗体依赖性细胞免疫效应子功能, 细胞毒性(ADCC)、抗体依赖性吞噬作用(ADCP)和抗体依赖性吞噬作用(ADCC)。 补体激活(ADC)都与小鼠的保护作用有关。但据 不确定非中和功能是否有助于人类的保护。因此,在这里,我们 旨在开发一种全面的,不可知的,样本保留的体液分析工具-广泛地 在前所未有的深度捕获Fc谱多样性-以定义额外的中和谱 追踪保护人类免受流感侵害的抗体。两组独特的油井 将对特征化的疫苗接种者进行分析,以确定保护的相关性和 中和抗体宽度的演变。与小鼠的机械解剖有关, 将进行剖析,以确定机制环节,以指导下一代疫苗的开发 旨在诱导针对流感的功能性广泛中和抗体的策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Daniel Lingwood其他文献

Daniel Lingwood的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Daniel Lingwood', 18)}}的其他基金

Defining the Fc-correlates of protection against influenza
定义流感保护的 Fc 相关因素
  • 批准号:
    10350602
  • 财政年份:
    2020
  • 资助金额:
    $ 60.13万
  • 项目类别:
Systemic coordination of pro-inflammatory immune reactions through dendritic cell-restricted sIL6R biogenesis
通过树突状细胞限制的 sIL6R 生物发生系统协调促炎性免疫反应
  • 批准号:
    10093221
  • 财政年份:
    2020
  • 资助金额:
    $ 60.13万
  • 项目类别:
Systemic coordination of pro-inflammatory immune reactions through dendritic cell-restricted sIL6R biogenesis
通过树突状细胞限制的 sIL6R 生物发生系统协调促炎性免疫反应
  • 批准号:
    10321243
  • 财政年份:
    2020
  • 资助金额:
    $ 60.13万
  • 项目类别:
Systemic coordination of pro-inflammatory immune reactions through dendritic cell-restricted sIL6R biogenesis
通过树突状细胞限制的 sIL6R 生物发生系统协调促炎性免疫反应
  • 批准号:
    10533314
  • 财政年份:
    2020
  • 资助金额:
    $ 60.13万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 60.13万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 60.13万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 60.13万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 60.13万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 60.13万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 60.13万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 60.13万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 60.13万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 60.13万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 60.13万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了